Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I randomized crossover pharmacokinetic comparison of two CO-1.01 formulations in advanced solid tumors
NL-OMON34352Phase 1Active, not recruiting
- Sponsor
- Clovis Oncology
- Start
- Apr 2011
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of gemcitabine elaidate in Nonhematologic neoplasms (2 arms), sponsored by Clovis Oncology. Primary endpoint: AUC ratio of the two formulations. Started Apr 2011; status: active, not recruiting.
02
Drugs
gemcitabine elaidate
03
Conditions
Nonhematologic neoplasms
Beyond the preview
Go deeper on NL-OMON34352.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON34352.